title: Current status of gene therapy for rheumatoid arthritis.
abstract: Despite the high prevalence of the disease, at present little effective pharmacological treatment of rheumatoid arthritis is available. Novel approaches utilising biological agents have resulted in the development of new antiarthritic and antiinflammatory agents, such as tumour necrosis factor-alpha (TNFalpha)-specific antibodies and interleukin-1 receptor antagonist (IL-1ra). Local gene therapy not only allows the pharmaceutical use of these biologicals, but also allows for continuous drug supply, which is necessary for chronic diseases like rheumatoid arthritis. We discuss the basics of rheumatoid arthritis therapy, candidate genes and possible gene transfer methods. A current clinical gene therapy trial is focusing on the IL-1 system using IL-1ra as a transgene. The transfer system, clinical protocol and preliminary results are described. After treatment of 11 patients we feel that gene therapy will offer potential as a new avenue to treat rheumatoid arthritis.
authors.affiliation: Orthogen Gentechnologie GmbH, Düsseldorf, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Reinecke
authors.forename: H
authors.initials: H
authors.lastname: Koch
authors.forename: H
authors.initials: H
authors.lastname: Meijer
authors.forename: M
authors.initials: M
authors.lastname: Granrath
authors.forename: K P
authors.initials: KP
authors.lastname: Schulitz
authors.forename: P
authors.initials: P
authors.lastname: Wehling